The Effects of Spirulina (Arthrospira Platensis) Dietary Supplement As An Adjunct Therapy For Children Aged 7–14 Years Old With Asthma: A Randomized – Double Blind Placebo Controlled Clinical Trial


Background The anti-infl ammatory effect of Spirulina has been demonstrated to inhibit histamine release from mast cell-mediated allergic reactions. Studies have documented the anti-infl ammatory and immunomodulatory properties of supplementation as an adjunct therapy for asthma.

Objective To determine the effects of Spirulina sup-plementation on asthma control and lung function among children aged 7-14 years old.

Methods This is a randomized, double-blind, placebo-controlled study wherein children 7 to 14 years old diagnosed with mild-to-moderate persis-tent asthma were randomly assigned to receive ei-ther Spirulina (1000 mg to 2000 mg daily) or pla-cebo for three months. Asthma Control Test (ACT) and Composite Asthma Severity Index (CASI) were used for patient report-based measures. Forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC, and peak expiratory fl ow rate (PEFR) were determined through spirom-etry. Post-supplementation assessment for 3 months was done.

Results A total of 39 patients (Spirulina = 20, placebo = 19) were enrolled in this trial. During the supplementation phase, both the Spirulina and placebo groups showed signifi cant improvement in ACT scores (Spirulina, p<0.0001; placebo, p = 0.19) compared to baseline. There was no sig-nifi cant change in CASI scores in both groups. However, during the post-supplementation phase, the Spirulina group showed signifi cantly sustained improvement on both the ACT (p<0.0001) and CASI scores (p<0.0001) compared to placebo. The FEV1 (p = 0.014), FVC (p = 0.008), and PEFR (p = 0.0001) of the Spirulina group signifi cantly im-proved by the end of supplementation. Overall, sig-nifi cant intergroup differences revealed only in FEV1 (p = 0.0002) and PEFR (p<0.0001).

Conclusion Daily supplementation with Spirulina signifi cantly improved asthma control, FEV1, and PEFR compared to placebo.

  1. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis and atopic eczema: ISAAC. The International Study of Asthma and Allergies Inchildhood (ISAAC) Steering Committee. Lancet. 1998;351:1225-1232.
  2. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2012 [Internet]. [updated 2012; cited 2014 Jul 29]. Available from:
  3. Bielory L. Complementary and alternative interventions in asthma, allergy, and immunology. Ann Allergy Asthma Immunol. 2004 Aug; 93:S45-S54.
  4. Philp J, Maselli J, Pachter l, et. al. Complementary and alternative medicine use and adherence with pediatric asthma treatment. Pediatrics. 2012 May;129:1-7.
  5. Kurt E, Bavbek S, Pasaoglu G, et. al. Use of alternative medicines by allergic patients in Turkey. Allergol et Immunopathol 2004;32(5):289-94.
  6. Nuhu A. Spirulina (Arthrospira): an important source of nutritional and medicinal compounds. Journal of Marine Biology. 2013 Jan; 2013:1-8.
  7. Kumari D, Jaffar B, Prasad M, et. al. Potential benefits of Spirulina platensis. Pharmanest. 2011 Sep–Dec;2:417-422.
  8. Kamenidou I, Aggelopoulos S, Batzios A. Natural medical attributes and benefits of Spirulina: segmentation based on consumers’ knowledge. J Med Plant Res. 2011 Jul:5(14);3192–9.
  9. Jassby A. Spirulina: a model for micro algae as human food. In: Lembi CA, Waaland JR, editors. Algae and human affairs. Cambridge: Cambridge University Press; 1988.
  10. Chamorro-Cevallo G, Garduño-Siciliano L, Barrón B, et. al. Chemoprotective effect of Spirulina (Arthrospira) against cyclophosphamide-induced mutagenicity in mice. Food Chem Toxicol. 2008 Feb;46(2):567–74.
  11. Orhan F, Sekerel B, Kocabas C, et. al. Complementary and alternative medicine in children with asthma. Ann Allergy Asthma Immunol. 2003;90:611–615.
  12. Hirashi T, Matsumoto M, Hazeki K, et. al. Activation of human innate immune system by Spirulina: augmentation of interferon production and NK cytotoxicity by oral administration of hot water extract of Spirulina plantesis. Int Immunopharmacol. 2002;2(4):423–34
  13. Shih C, Cheng S, Wong C, et. al. Anti-inflammatory and anti-hyperalgesic activity of C-phycocyanin. Anesth Analg. 2009:108;1303–10.
  14. Chen LL, Zhang SF, Huang DN, et. al. Experimental study of Spirulina platensis in treating allergic rhinitis in rats. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2005 Feb;30(1):96–8.
  15. Reddy CM, Bhat VB, Kiranmai G, et al.: Selective inhibition of cyclooxygenase-2 by C-phycocyanin, a biliprotein from Spirulina platensis. Biochem Biophys Res Commun 2000;277:599–603.
  16. Romay C, Armesto J, Remirez D, et al.: Antioxidant and anti-inflammatory properties of C-phycocyanin from blue-green algae. Inflamm Res 1998;47:36–41.
  17. Hayashi O, Hirahashi T, Katoh T, et al.: Class specific influence of dietary Spirulina platensis on antibody production in mice. J Nutr Sci Vitaminol (Tokyo) 1998;44:841–851.
  18. Evets L. Means to normalize the levels of immunoglobulin E, using the food supplement Spirulina [Internet]. 1994. Grodenski State Medical Univ. Russian Federation Committee of Patents and Trade. Patent (19) RU (11)2005486.1994. Available from:
  19. Cingi C, Conk-Dalay M, Cakli H, et. al. The effects of spirulina on allergic rhinitis. Eur Arch Otorhinolaryngol. 2008;265:1219–23.
  20. Mao T, Van de Water J, Gershwin M. Effects of a Spirulina-based dietary supplement on cytokine production from allergic rhinitis patients. J Med Food. 2005;8(1);27–30.
  21. Labhe R, Mani U, Iyer U, et. al. The effect of spirulina in the treatment of bronchial asthma. J Nutraceut Function Med Foods. 2001;3(4):53–60.
  22. Busse W. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma–Summary Report 2007. J Allergy Clin Immunol 2007; -138.
  23. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2014 [Internet]. [updated 2014; cited 2014 Aug 20]. Available from:
  24. Wildfire JJ, Gergen PJ, Sorkness CA, Mitchell HE, Calatroni A, Kattan M, et al. Development and validation of the Composite Asthma Severity Index—an outcome measure for use in children and adolescents. J Allergy Clin Immunol. 2012 Mar;129(3):694–701. doi: 10.1016/j.jaci.2011.12.962.
  25. Dallal G. [Internet]. 2007 [updated 2013 Mar 29; cited 2014 Jul 29]. Available from:
  26. Remirez D, Ledon N, Gonzalez R. Role of histamine in the inhibitory effects of phycocyanin in experimental models of allergic inflammatory response. Mediators of Inflammation. 2002:11; 81–85.
  27. Yang H, Lee E, Kim H. Spirulina platensis inhibits anaphylactic reaction. Life Sciences. 1997;61:1237–44.
  28. Romay C, Ledon N, Gonzalez R. Effects of phycocyanin extract on prostaglandin E2 levels in mouse ear inflammation test. Arzneim Forsch/ Drug Res 2000; 50: 1106–1109.
  29. Romay C, Ledon N, Gonzalez R. Phycocyanin extract reduces leukotrienes B4 levels in arachidonic acid-induced mouse ear inflammation test. J Phar Pharmacol 1999; 51: 641–642.
  30. Mainardi T, Kapoor S, Bielory L. Complementary and alternative medicine: Herbs, phytochemicals and vitamins and their immunologic effects. J Allergy Clin Immunol, 2009;123:283–94.
  31. FDA. GRN 000127. Spirulina, the dried biomass of Arthrospira platensis [Internet]. 2003. Available from: htttp://
  32. Chamorro GA, Herrera G, Salazar M, et. al. Subchronic toxicity study in rats fed Spirulina. J Pharm Belg. 1988;43(1):29–36.
  33. Chamorro G, Salazar M, Favila L, et. al. Pharmacology and toxicology of Spirulina alga. Rev Invest Clin. 1996;48:389–99.
  34. Simpore J, Kabore F, Zongo F, Dansou D, Bere A, Pignatelli S, et. al. Nutrition rehabilitation of undernourished children utilizing Spiruline and Misola. Nutr J. 2006;5:3–7.
  35. Simpore J, Zongo F, Kabore F, Dansou D, Bere A, Nikiema JB, et. al. Nutrition rehabilitation of HIV-infected and HIV-negative undernourished children utilizing spirulina. Ann Nutr Metab. 2005;49:373–80.



Conflict(s) of Interest:There are no conflicts of interest in the authorship or publication of this manuscript.


Financial support: No financial support was provided in this manuscript. Material support for this research and work are clearly identified in the acknowledgments section of this manuscript.

Articles related to the one you are viewing

There are currently no results to show, please try again later

CC BY: Open Access Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit